Surprise, surprise: Impax Labs, looking to bulk up amid generics pricing pressure and newly helmed by M&A specialist Paul Bisaro, has struck a deal.
What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
In the wake of Hurricane Maria, J&J says the company's Puerto Rico manufacturing plants "fared well," but "intermittent" shortages…
Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis.
Investors are demanding change at top drug distributors after an investigation exposed lax controls and lots of Capitol Hill arm-twisting.
FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.
Mylan and other generics makers urged a Texas judge to call Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe a "sham."
Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.
Sugarpod, a voice-enabled diabetes plan that uses Amazon's Alexa to help people complete daily tasks by speaking, won Merck’s tech challenge.